In plain language
IGF-1 DES is a shortened form of insulin-like growth factor 1, missing its first three amino acids, which makes it bind less to carrier proteins and act more potently in research settings. Almost all data comes from cell and animal studies. There are no human outcome trials, so its effects and safety in people are not established.
What it is explored for
IGF-1 DES is an interesting research variant of IGF-1, engineered to slip past carrier proteins and act more potently in laboratory models. Its pharmacology is reasonably well characterized in cells and animals, which is part of the curiosity around it. It is important to be clear, though, that there are no human outcome trials, so benefit and safety in people are not established. Here is where it is studied.
- Muscle growth and repair research
- IGF-1 receptor signaling studies
- Local tissue potency research
- Recovery and lean-mass interest
- Preclinical growth-factor research
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
IGF-1 DES lacks the first three amino acids of IGF-1, which sharply reduces its binding to IGF-binding proteins and is reported to increase its local potency in research models.
- IGF-1 receptor activation. Acts at the IGF-1 receptor to drive growth, protein synthesis, and cell proliferation signals.
- Reduced binding-protein affinity. Removing the first three residues lowers binding to IGFBPs, leaving more free, active peptide in cell studies.
- Reported higher local potency. In laboratory models it is described as more potent than standard IGF-1 at comparable amounts.
These properties are characterized mainly in cell and animal studies. Human outcome trials are lacking.
Evidence summary
Evidence for IGF-1 DES is limited and largely preclinical. Its pharmacology, reduced binding-protein affinity and higher local potency, is reasonably characterized in the lab, but there are no human outcome trials supporting muscle, recovery, or performance claims. Benefit and safety in people are not established.
Reported safety & side effects
Human safety data is lacking. As a potent IGF-1 receptor agonist, theoretical concerns include hypoglycemia and growth signaling that could affect abnormal tissue. Long-term effects in people are unknown.
Frequently asked
Is IGF-1 DES FDA-approved?
No. IGF-1 DES is not approved by the FDA for any use. It is sold as a research chemical and is not an approved medicine.
What makes IGF-1 DES different from regular IGF-1?
It is missing the first three amino acids, which reduces how much it binds to carrier proteins in the blood. In laboratory models this leaves more active peptide and makes it appear more potent than standard IGF-1.
Is there human evidence it builds muscle?
No. The data is mostly from cell and animal studies. There are no human outcome trials, so muscle benefit and safety in people are not established.